These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21347423)

  • 21. A system for efficient generation of adenovirus protein IX-producing helper cell lines.
    Vellinga J; Uil TG; de Vrij J; Rabelink MJ; Lindholm L; Hoeben RC
    J Gene Med; 2006 Feb; 8(2):147-54. PubMed ID: 16288495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Development of a novel adenovirus vector exhibiting microRNA-mediated suppression of the leaky expression of adenovirus genes].
    Shimizu K; Sakurai F; Tachibana M; Mizuguchi H
    Yakugaku Zasshi; 2012; 132(12):1407-12. PubMed ID: 23208048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spacers increase the accessibility of peptide ligands linked to the carboxyl terminus of adenovirus minor capsid protein IX.
    Vellinga J; Rabelink MJ; Cramer SJ; van den Wollenberg DJ; Van der Meulen H; Leppard KN; Fallaux FJ; Hoeben RC
    J Virol; 2004 Apr; 78(7):3470-9. PubMed ID: 15016870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modification of pIX or hexon based on fiberless Ad vectors is not effective for targeted Ad vectors.
    Kurachi S; Koizumi N; Tashiro K; Sakurai H; Sakurai F; Kawabata K; Nakagawa S; Mizuguchi H
    J Control Release; 2008 Apr; 127(1):88-95. PubMed ID: 18258327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Capsomer-specific fluorescent labeling of adenoviral vector particles allows for detailed analysis of intracellular particle trafficking and the performance of bioresponsive bonds for vector capsid modifications.
    Espenlaub S; Corjon S; Engler T; Fella C; Ogris M; Wagner E; Kochanek S; Kreppel F
    Hum Gene Ther; 2010 Sep; 21(9):1155-67. PubMed ID: 20384482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peptide targeting of adenoviral vectors to augment tumor gene transfer.
    Ballard EN; Trinh VT; Hogg RT; Gerard RD
    Cancer Gene Ther; 2012 Jul; 19(7):476-88. PubMed ID: 22595794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Formulation and in vitro and in vivo evaluation of a cationic emulsion as a vehicle for improving adenoviral gene transfer.
    Kim SY; Lee SJ; Lim SJ
    Int J Pharm; 2014 Nov; 475(1-2):49-59. PubMed ID: 25138255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a novel efficient method to construct an adenovirus library displaying random peptides on the fiber knob.
    Yamamoto Y; Goto N; Miura K; Narumi K; Ohnami S; Uchida H; Miura Y; Yamamoto M; Aoki K
    Mol Pharm; 2014 Mar; 11(3):1069-74. PubMed ID: 24380399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Derivation of a triple mosaic adenovirus based on modification of the minor capsid protein IX.
    Tang Y; Le LP; Matthews QL; Han T; Wu H; Curiel DT
    Virology; 2008 Aug; 377(2):391-400. PubMed ID: 18570971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.
    Roberts DM; Nanda A; Havenga MJ; Abbink P; Lynch DM; Ewald BA; Liu J; Thorner AR; Swanson PE; Gorgone DA; Lifton MA; Lemckert AA; Holterman L; Chen B; Dilraj A; Carville A; Mansfield KG; Goudsmit J; Barouch DH
    Nature; 2006 May; 441(7090):239-43. PubMed ID: 16625206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting.
    Jönsson F; Hagedorn C; Kreppel F
    J Vis Exp; 2018 Oct; (140):. PubMed ID: 30417881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hexon modification to improve the activity of oncolytic adenovirus vectors against neoplastic and stromal cells in pancreatic cancer.
    Lucas T; Benihoud K; Vigant F; Schmidt CQ; Wortmann A; Bachem MG; Simmet T; Kochanek S
    PLoS One; 2015; 10(2):e0117254. PubMed ID: 25692292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of fiber detargeting on adenovirus-mediated innate and adaptive immune activation.
    Schoggins JW; Nociari M; Philpott N; Falck-Pedersen E
    J Virol; 2005 Sep; 79(18):11627-37. PubMed ID: 16140740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluorescently tagged canine adenovirus via modification with protein IX-enhanced green fluorescent protein.
    Le LP; Li J; Ternovoi VV; Siegal GP; Curiel DT
    J Gen Virol; 2005 Dec; 86(Pt 12):3201-3208. PubMed ID: 16298964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Altering the Ad5 packaging domain affects the maturation of the Ad particles.
    Alba R; Cots D; Ostapchuk P; Bosch A; Hearing P; Chillon M
    PLoS One; 2011; 6(5):e19564. PubMed ID: 21611162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
    Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
    Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of adenovirus capsid labeling versus transgene expression.
    Li J; Fatima A; Komarova S; Ugai H; Uprety P; Roth JC; Wang M; Oster RA; Curiel DT; Matthews QL
    Virol J; 2010 Jan; 7():21. PubMed ID: 20102632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Noninvasive visualization of adenovirus replication with a fluorescent reporter in the E3 region.
    Ono HA; Le LP; Davydova JG; Gavrikova T; Yamamoto M
    Cancer Res; 2005 Nov; 65(22):10154-8. PubMed ID: 16287998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses.
    Worgall S; Busch A; Rivara M; Bonnyay D; Leopold PL; Merritt R; Hackett NR; Rovelink PW; Bruder JT; Wickham TJ; Kovesdi I; Crystal RG
    J Virol; 2004 Mar; 78(5):2572-80. PubMed ID: 14963160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach.
    Matthews QL; Yang P; Wu Q; Belousova N; Rivera AA; Stoff-Khalili MA; Waehler R; Hsu HC; Li Z; Li J; Mountz JD; Wu H; Curiel DT
    Virol J; 2008 Aug; 5():98. PubMed ID: 18718011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.